Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells. (Q53629318)

16 May 2018

title

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells. (English)

1 reference

16 May 2018

0 references

0 references

12

A Tefferi

1 reference

16 May 2018

A Pardanani

1

1 reference

16 May 2018

T Lasho

2

1 reference

16 May 2018

D Chen

3

1 reference

16 May 2018

T K Kimlinger

4

1 reference

16 May 2018

C Finke

5

1 reference

16 May 2018

D Zblewski

6

1 reference

16 May 2018

M M Patnaik

7

1 reference

16 May 2018

K K Reichard

8

1 reference

16 May 2018

E Rowinsky

9

1 reference

16 May 2018

C A Hanson

10

1 reference

16 May 2018

C Brooks

11

1 reference

16 May 2018

publication date

2 February 2015

1 reference

16 May 2018

published in

Leukemia

1 reference

16 May 2018

volume

29

1 reference

16 May 2018

issue

7

1 reference

16 May 2018

page(s)

1605-1608

1 reference

16 May 2018

A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all thr

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.16

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25640886

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25640886

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Failure to detect IL-3-binding sites on human mast cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25640886

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2015.16

1 reference

16 May 2018

1 reference

16 May 2018